

References

1. Stepanova M, Wai H, Saab S, Mishra A, Venkatesan C, Younossi ZM. The outcomes of adult liver transplants in the United States from 1987 to 2013. *Liver Int.* 2015 Aug;35(8):2036–41.
2. Serrano MT, Sabroso S, Esteban LM, Berenguer M, Fondevila C, Lorente S, et al. Mortality and Causes of Death After Liver Transplantation: Analysis of Sex Differences in a Large Nationwide Cohort. *Transpl Int.* 2022 May 9;35:10263.
3. Razonable RR, Humar A. Cytomegalovirus in solid organ transplant recipients-Guidelines of the American Society of Transplantation Infectious Diseases Community of Practice. *Clin Transplant.* 2019 Sep;33(9):e13512.
4. Fishman JA. Infection in Organ Transplantation. *Am J Transplant.* 2017 Apr;17(4):856–79.
5. Yadav DK, Adhikari VP, Yadav RK, Singh A, Huang X, Zhang Q, et al. Antiviral prophylaxis or preemptive therapy for cytomegalovirus after liver transplantation?: A systematic review and meta-analysis. *Front Immunol.* 2022 Nov 10;13:953210.
6. Singh N, Winston DJ, Razonable RR, Lyon GM, Silveira FP, Wagener MM, et al. Effect of Preemptive Therapy vs Antiviral Prophylaxis on Cytomegalovirus Disease in Seronegative Liver Transplant Recipients With Seropositive Donors. *JAMA.* 2020 Apr 14;323(14):1378–87.
7. Kumar L, Dasgupta S, Murray-Krezan C, Singh N, Rakita RM, Fisher CE, et al. Association of Cytomegalovirus (CMV) DNAemia With Long-Term Mortality in a Randomized Trial of Preemptive Therapy and Antiviral Prophylaxis for Prevention of CMV Disease in High-Risk Donor Seropositive, Recipient Seronegative Liver Transplant Recipients. *Clin Infect Dis.* 2024 Mar 20;78(3):719–22.
8. Singh N, Winston DJ, Razonable RR, Lyon GM, Silveira FP, Wagener MM, et al. Cost-effectiveness of Preemptive Therapy Versus Prophylaxis in a Randomized Clinical Trial for the Prevention of Cytomegalovirus Disease in Seronegative Liver Transplant Recipients With Seropositive Donors. *Clin Infect Dis.* 2021 Nov 2;73(9):e2739–45.